RxSight Management
Management criteria checks 2/4
RxSight's CEO is Ron Kurtz, appointed in Jan 2016, has a tenure of 9.75 years. total yearly compensation is $6.98M, comprised of 9.7% salary and 90.3% bonuses, including company stock and options. directly owns 2.02% of the company’s shares, worth $7.29M. The average tenure of the management team and the board of directors is 6.3 years and 4.2 years respectively.
Key information
Ron Kurtz
Chief executive officer
US$7.0m
Total compensation
| CEO salary percentage | 9.71% |
| CEO tenure | 9.8yrs |
| CEO ownership | 2.0% |
| Management average tenure | 6.3yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern?
Sep 22Investors Don't See Light At End Of RxSight, Inc.'s (NASDAQ:RXST) Tunnel And Push Stock Down 39%
Aug 07
Time To Worry? Analysts Just Downgraded Their RxSight, Inc. (NASDAQ:RXST) Outlook
Jul 19The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Jun 18
South Korea And UK Approvals Will Expand Market Adoption
International expansion and regulatory approvals are poised to significantly boost revenue by entering new markets and enhancing clinical support.RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
Apr 04RxSight, Inc. (NASDAQ:RXST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Mar 08RxSight, Inc. (NASDAQ:RXST) Just Reported, And Analysts Assigned A US$44.80 Price Target
Feb 28The Price Is Right For RxSight, Inc. (NASDAQ:RXST)
Dec 06RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
Nov 29We Think RxSight (NASDAQ:RXST) Can Easily Afford To Drive Business Growth
Sep 04Investing In The Future Of Cataract Surgery: The RxSight Advantage
Aug 13With A 27% Price Drop For RxSight, Inc. (NASDAQ:RXST) You'll Still Get What You Pay For
Aug 03Why RxSight, Inc. (NASDAQ:RXST) Could Be Worth Watching
Jul 12RxSight: Great Business Model, Stretched Valuations
Jul 10A Look At The Intrinsic Value Of RxSight, Inc. (NASDAQ:RXST)
Jun 20RxSight, Inc. (NASDAQ:RXST) Analysts Are Pretty Bullish On The Stock After Recent Results
May 09RxSight (NASDAQ:RXST) Is In A Strong Position To Grow Its Business
May 05RxSight: Promising Technology, Uncertain Profitability - A Hold Recommendation
May 01Why We're Not Concerned About RxSight, Inc.'s (NASDAQ:RXST) Share Price
Apr 16Is It Time To Consider Buying RxSight, Inc. (NASDAQ:RXST)?
Mar 24RxSight Stock: Time To Refocus Following Eye Watering Rally
Jan 16RxSight, Inc. (NASDAQ:RXST) Stocks Shoot Up 30% But Its P/S Still Looks Reasonable
Jan 09We Think RxSight (NASDAQ:RXST) Can Afford To Drive Business Growth
Dec 21Revenues Tell The Story For RxSight, Inc. (NASDAQ:RXST) As Its Stock Soars 28%
Nov 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | -US$32m |
| Mar 31 2025 | n/a | n/a | -US$27m |
| Dec 31 2024 | US$7m | US$678k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$31m |
| Jun 30 2024 | n/a | n/a | -US$37m |
| Mar 31 2024 | n/a | n/a | -US$44m |
| Dec 31 2023 | US$3m | US$633k | -US$49m |
| Sep 30 2023 | n/a | n/a | -US$55m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$62m |
| Dec 31 2022 | US$1m | US$563k | -US$67m |
| Sep 30 2022 | n/a | n/a | -US$67m |
| Jun 30 2022 | n/a | n/a | -US$63m |
| Mar 31 2022 | n/a | n/a | -US$59m |
| Dec 31 2021 | US$5m | US$445k | -US$49m |
| Sep 30 2021 | n/a | n/a | -US$15m |
| Jun 30 2021 | n/a | n/a | US$4m |
| Mar 31 2021 | n/a | n/a | US$17m |
| Dec 31 2020 | US$741k | US$310k | US$3m |
Compensation vs Market: Ron's total compensation ($USD6.98M) is above average for companies of similar size in the US market ($USD2.32M).
Compensation vs Earnings: Ron's compensation has increased whilst the company is unprofitable.
CEO
Ron Kurtz (62 yo)
Dr. Ronald M. Kurtz, also known as Ron, M.D., serves as Chief Executive Officer at RxSight, Inc. (formerly Calhoun Vision) since January 2016 and also serves as its Director since February 2016 and also se...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-President | 9.8yrs | US$6.98m | 2.02% $ 7.3m | |
| Co-President & Chief Commercial Officer | 10.3yrs | US$5.80m | 1.21% $ 4.4m | |
| Co-President & CFO | 8.7yrs | US$5.80m | 0.094% $ 337.5k | |
| Co-President & COO | 6.3yrs | US$5.82m | 0.16% $ 590.1k | |
| Chief Technology Officer | no data | no data | no data | |
| Executive VP of Manufacturing & Commercial Operations | 3.8yrs | no data | no data | |
| Executive VP of Clinical & Regulatory Affairs | 3.6yrs | no data | no data | |
| Executive VP of Quality & Infrastructure Operations | 2.4yrs | no data | no data |
Experienced Management: RXST's management team is seasoned and experienced (6.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-President | 9.7yrs | US$6.98m | 2.02% $ 7.3m | |
| Director | 8.9yrs | US$201.20k | 0.12% $ 425.5k | |
| Independent Director | 4.2yrs | US$214.95k | 0.074% $ 266.5k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 10.3yrs | US$214.95k | 0.095% $ 342.7k | |
| Independent Chairman of the Board | 10.8yrs | US$262.45k | 1.32% $ 4.8m | |
| Independent Director | 3.8yrs | US$209.95k | 0.061% $ 218.2k | |
| Independent Director | 4.2yrs | US$219.95k | 0.074% $ 266.5k | |
| Independent Director | 4.2yrs | US$217.45k | 0.074% $ 266.5k | |
| Independent Director | 3.8yrs | US$204.95k | 0.018% $ 65.0k |
Experienced Board: RXST's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/06 23:02 |
| End of Day Share Price | 2025/10/06 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RxSight, Inc. is covered by 14 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Craig Bijou | BofA Global Research |
| Michael Gorman | BTIG |